JP2012153722A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012153722A5 JP2012153722A5 JP2012112647A JP2012112647A JP2012153722A5 JP 2012153722 A5 JP2012153722 A5 JP 2012153722A5 JP 2012112647 A JP2012112647 A JP 2012112647A JP 2012112647 A JP2012112647 A JP 2012112647A JP 2012153722 A5 JP2012153722 A5 JP 2012153722A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- compound
- use according
- pharmaceutical formulation
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- IBXPYPUJPLLOIN-UHFFFAOYSA-N Cc([n]1C)ncc1[N+]([O-])=O Chemical compound Cc([n]1C)ncc1[N+]([O-])=O IBXPYPUJPLLOIN-UHFFFAOYSA-N 0.000 description 1
- 0 Cc1ccc(*)[s]1 Chemical compound Cc1ccc(*)[s]1 0.000 description 1
- FNEJQOIAGPBETK-UHFFFAOYSA-N Cc1ccc(O)[o]1 Chemical compound Cc1ccc(O)[o]1 FNEJQOIAGPBETK-UHFFFAOYSA-N 0.000 description 1
- HLEIGKIQLNEZMS-UHFFFAOYSA-N Cc1cnc(N)[n]1C Chemical compound Cc1cnc(N)[n]1C HLEIGKIQLNEZMS-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US69575505P | 2005-06-29 | 2005-06-29 | |
US60/695,755 | 2005-06-29 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008519666A Division JP5180824B2 (ja) | 2005-06-29 | 2006-06-29 | ホスホルアミデートアルキル化剤プロドラッグ |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2012153722A JP2012153722A (ja) | 2012-08-16 |
JP2012153722A5 true JP2012153722A5 (fr) | 2013-02-07 |
JP5781007B2 JP5781007B2 (ja) | 2015-09-16 |
Family
ID=37596083
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008519666A Active JP5180824B2 (ja) | 2005-06-29 | 2006-06-29 | ホスホルアミデートアルキル化剤プロドラッグ |
JP2012112647A Active JP5781007B2 (ja) | 2005-06-29 | 2012-05-16 | ホスホルアミデートアルキル化剤プロドラッグ |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008519666A Active JP5180824B2 (ja) | 2005-06-29 | 2006-06-29 | ホスホルアミデートアルキル化剤プロドラッグ |
Country Status (24)
Country | Link |
---|---|
US (4) | US8003625B2 (fr) |
EP (2) | EP2336141B1 (fr) |
JP (2) | JP5180824B2 (fr) |
KR (1) | KR101198571B1 (fr) |
CN (2) | CN102746336B (fr) |
AU (2) | AU2006263433B8 (fr) |
BR (1) | BRPI0612845A8 (fr) |
CA (1) | CA2613312C (fr) |
CY (1) | CY1113250T1 (fr) |
DK (1) | DK1896040T3 (fr) |
ES (2) | ES2579235T3 (fr) |
HK (1) | HK1113754A1 (fr) |
HR (1) | HRP20120803T1 (fr) |
IL (1) | IL188236A (fr) |
NO (1) | NO334420B1 (fr) |
NZ (1) | NZ565378A (fr) |
PL (1) | PL1896040T3 (fr) |
PT (1) | PT1896040E (fr) |
RS (1) | RS52505B (fr) |
RU (1) | RU2414475C2 (fr) |
SI (1) | SI1896040T1 (fr) |
TW (1) | TWI384989B (fr) |
WO (1) | WO2007002931A2 (fr) |
ZA (1) | ZA200800314B (fr) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS52505B (en) | 2005-06-29 | 2013-04-30 | Threshold Pharmaceuticals Inc. | PHOSPHORAMIDATE ALKYLATER PRODUCTS |
EP2114157B1 (fr) * | 2006-12-26 | 2021-05-26 | ImmunoGenesis, Inc. | Promédicament d'alkylation de phosphoramidate pour le traitement du cancer |
US8765690B2 (en) | 2007-04-05 | 2014-07-01 | Threshold Pharmaceuticals, Inc. | Treatment of cancer with glufosfamide in patients not receiving insulin therapy |
WO2009018163A1 (fr) * | 2007-07-27 | 2009-02-05 | Threshold Pharmaceuticals, Inc. | Promédicaments d'anthracyclines activés par une hypoxie |
UA104579C2 (uk) | 2007-12-10 | 2014-02-25 | Байокрист Фармасьютикалз, Инк. | Спосіб лікування раку кровотворної системи із застосуванням фородезину у комбінації з ритуксимабом |
CN102256966B (zh) | 2008-10-17 | 2016-02-10 | 白头生物医学研究所 | 可溶性mTOR复合物和其调节剂 |
WO2010048330A1 (fr) | 2008-10-21 | 2010-04-29 | Threshold Pharmaceuticals, Inc. | Traitement du cancer à l’aide de promédicaments activés par l’hypoxie |
AU2011276590A1 (en) * | 2010-06-28 | 2013-01-31 | Threshold Pharmaceuticals, Inc. | Treatment of blood cancer |
RU2597844C2 (ru) * | 2010-07-12 | 2016-09-20 | Тресхолд Фармасьютикалз, Инк. | Введение гипоксически активируемых пролекарств и средств, препятствующих ангиогенезу, для лечения рака |
CN103458896B (zh) * | 2011-04-01 | 2016-02-10 | 施瑞修德制药公司 | 用于治疗癌症的方法 |
EP2696858A4 (fr) * | 2011-04-15 | 2014-09-03 | Threshold Pharmaceuticals Inc | Forme posologique unitaire pour administration orale |
WO2012145684A1 (fr) * | 2011-04-22 | 2012-10-26 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Inducteurs d'hypoxie transitoire et leur utilisation |
CN102850397B (zh) * | 2011-06-29 | 2015-02-18 | 北京大学 | 多靶点抗肿瘤化合物及其制备方法和应用 |
CN102924507A (zh) * | 2011-11-10 | 2013-02-13 | 安徽四维药业有限公司 | 一种抗肿瘤化合物及其制备方法与应用、药物组合物 |
US20150005262A1 (en) * | 2011-12-22 | 2015-01-01 | Threshold Pharmaceuticals, Inc. | Hypoxia activated prodrugs and mtor inhibitors for treating cancer |
EP2793882A4 (fr) | 2011-12-22 | 2015-04-29 | Threshold Pharmaceuticals Inc | Administration de promédicaments activés par l'hypoxie en combinaison à des inhibiteurs de chk1 pour le traitement du cancer |
WO2013126539A1 (fr) * | 2012-02-21 | 2013-08-29 | Threshold Pharmaceuticals Inc. | Traitement du cancer |
WO2013154778A1 (fr) | 2012-04-11 | 2013-10-17 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs ciblant l'hôte du virus de la dengue et d'autres virus |
EP2870169A1 (fr) * | 2012-07-03 | 2015-05-13 | Bristol-Myers Squibb Company | Procédé de préparation de dérivés de phosphoramidates enrichis en diastéréo-isomères de composés de nucléosides, destinés au traitement d'infections virales |
WO2014062856A1 (fr) | 2012-10-16 | 2014-04-24 | Halozyme, Inc. | Hypoxie et hyaluronane et leurs marqueurs pour le diagnostic et la surveillance de maladies et de pathologies, et méthodes associées |
WO2014063054A1 (fr) | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs de kinase moelle osseuse sur chromosome x (bmx) et leurs utilisations |
WO2014069063A1 (fr) | 2012-10-29 | 2014-05-08 | 京セラ株式会社 | Capteur d'onde acoustique de surface |
CN105792845A (zh) | 2013-07-26 | 2016-07-20 | 施瑞修德制药公司 | 使用低氧活化的前药与紫杉烷类化合物的组合治疗胰腺癌 |
WO2015025283A2 (fr) | 2013-08-20 | 2015-02-26 | Stichting Maastricht Radiation Oncology "Maastro-Clinic" | Inhibiteurs d'anhydrsase carbonique à double action |
EP3055295A1 (fr) * | 2013-10-10 | 2016-08-17 | Merck Patent GmbH | Synthèse d'ester d'acide 1-alkyl-2-amino-imidazol-5-carboxylique utilisant des dérivés d'ester de n-alkyle-glycine substitués par calpha |
WO2015069489A1 (fr) | 2013-11-06 | 2015-05-14 | Merck Patent Gmbh | Biomarqueur prédictif pour thérapie à base de promédicament activé par l'hypoxie |
CN104628772A (zh) * | 2013-11-07 | 2015-05-20 | 四川恒康发展有限责任公司 | 一种抗肿瘤前药及其激活剂、组合物和应用 |
AU2015217221A1 (en) * | 2014-02-13 | 2016-08-11 | Ligand Pharmaceuticals, Inc. | Prodrug compounds and their uses |
US10131683B2 (en) | 2014-07-17 | 2018-11-20 | Molecular Templates, Inc. | TH-302 solid forms and methods related thereto |
MY192888A (en) * | 2015-03-10 | 2022-09-14 | Ascentawits Pharmaceuticals Ltd | Dna alkylating agents |
MY198613A (en) | 2015-04-02 | 2023-09-11 | Ascenta Pharmaceuticals Ltd | Nitrobenzyl derivatives of anti-cancer agents |
PL412787A1 (pl) | 2015-06-22 | 2017-01-02 | Magdalena Król | Oparty na makrofagach celowany system dostarczania związków związanych z ferrytyną |
CN105037427B (zh) * | 2015-06-22 | 2017-05-31 | 石家庄学院 | 丹参酮iia亚乙基亚胺磷酸酯衍生物及其制备方法与应用 |
CN108024974B (zh) * | 2015-06-24 | 2023-11-14 | 免疫原公司 | 含有dna烷化剂的氮丙啶 |
CA2990696C (fr) * | 2015-11-16 | 2024-01-02 | Obi Pharma, Inc. | (r)- et (s)-1-(3-(3-n,n-dimethylaminocarbonyl)phenoxyl-4-nitrophenyl)-1-ethyl-n,n'-bis(ethylene)phosphoramidate, compositions et procedes pour leur utilisation et preparation |
CA3019945A1 (fr) * | 2016-04-04 | 2017-10-12 | Rutgers, The State University Of New Jersey | Poisons de topoisomerase |
SI3565806T1 (sl) | 2017-01-06 | 2022-07-29 | Rivus Pharmaceuticals, Inc. | Novi fenilni derivati |
EP3737676B1 (fr) | 2018-01-09 | 2024-03-06 | Ligand Pharmaceuticals, Inc. | Composés acétal et leurs utilisations thérapeutiques |
CA3103205A1 (fr) | 2018-06-13 | 2019-12-19 | Amphista Therapeutics Ltd | Molecules bifonctionnelles pour cibler l'uchl5 |
CN112533918A (zh) | 2018-06-13 | 2021-03-19 | 安菲斯塔治疗有限责任公司 | 用于靶向Rpn11的双功能分子 |
WO2019238886A1 (fr) | 2018-06-13 | 2019-12-19 | University Of Dundee | Molécules bifonctionnelles pour le ciblage de l'usp14 |
CN110746459A (zh) * | 2018-07-24 | 2020-02-04 | 上海喀露蓝科技有限公司 | 一种艾伏磷酰胺的制备方法 |
EP3650046A1 (fr) | 2018-11-08 | 2020-05-13 | Cellis AG | Système d'administration d'ingrédients actifs ciblés à base de cellules souches mésenchymateuses |
CN109705187B (zh) * | 2019-01-29 | 2021-08-20 | 石家庄学院 | 一种雷公藤红素衍生物及其制备方法与应用 |
CN112755001B (zh) * | 2019-11-01 | 2022-04-12 | 深圳艾欣达伟医药科技有限公司 | 口服给药的固体剂型药物 |
WO2021185986A1 (fr) | 2020-03-18 | 2021-09-23 | Cellis Ag | Variants de ferritine présentant une stabilité, une aptitude à la complexation et une affinité pour le récepteur de transferrine accrues |
CA3212386A1 (fr) | 2021-03-18 | 2022-09-22 | Alessandro ARCOVITO | Variants de ferritine ayant une stabilite et une capacite de complexation accrues |
WO2023025291A1 (fr) | 2021-08-27 | 2023-03-02 | 深圳艾欣达伟医药科技有限公司 | Solution de formulation lyophilisée, formulation lyophilisée, procédé et utilisation associés |
CN118076359A (zh) | 2021-08-27 | 2024-05-24 | 深圳艾欣达伟医药科技有限公司 | 使用th-302治疗parp抑制剂耐药的患者 |
WO2024056413A1 (fr) | 2022-09-13 | 2024-03-21 | Cellis Ag | Système isolé d'administration ciblée pour le traitement du gliome |
WO2024112663A1 (fr) | 2022-11-21 | 2024-05-30 | Rivus Pharmaceuticals, Inc. | Dérivés de phényle enrichis en deutérium pour le traitement de troubles ou d'états associés aux mitochondries |
Family Cites Families (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3652579A (en) | 1969-06-26 | 1972-03-28 | Hoffmann La Roche | 1-methyl-2-substituted 5-nitroimidazoles |
DE2229248C3 (de) | 1971-07-30 | 1980-03-27 | Gruppo Lepetit S.P.A., Mailand (Italien) | 5-Iminomethyl-2-nitroimidazoI-Derivate und Verfahren zu deren Herstellung |
US4921963A (en) | 1987-04-13 | 1990-05-01 | British Columbia Cancer Foundation | Platinum complexes with one radiosensitizing ligand |
JPH0819111B2 (ja) | 1987-10-22 | 1996-02-28 | ポーラ化成工業株式会社 | 2―ニトロイミダゾール誘導体及びこれを有効成分とする放射線増感剤 |
US5190929A (en) | 1988-05-25 | 1993-03-02 | Research Corporation Technologies, Inc. | Cyclophosphamide analogs useful as anti-tumor agents |
US4908356A (en) | 1988-05-25 | 1990-03-13 | Research Corporation Technologies, Inc. | Aldophosphamide derivatives useful as antitumor agents |
US5403932A (en) | 1988-05-25 | 1995-04-04 | Research Corporation Technologies, Inc. | Phosphoramidates useful as antitumor agents |
DE3835772A1 (de) | 1988-10-20 | 1990-04-26 | Deutsches Krebsforsch | Tumorhemmende saccharid-konjugate |
JP2626727B2 (ja) | 1990-01-26 | 1997-07-02 | ポーラ化成工業株式会社 | 2―ニトロイミダゾール誘導体、その製造法及びこれを有効成分とする放射線増感剤 |
HU9201539D0 (en) | 1990-09-11 | 1992-08-28 | Kortec Ag | Method and device for gasifying gasifiable materials and/or transforming gas as well as heat exchanger of high temperature for executing said method |
US5233031A (en) | 1991-09-23 | 1993-08-03 | University Of Rochester | Phosphoramidate analogs of 2'-deoxyuridine |
AU681337B2 (en) | 1991-10-23 | 1997-08-28 | Cancer Research Campaign Technology Limited | Bacterial nitroreductase for the reduction of CB 1954 and analogues thereof to a cytotoxic form |
US5750782A (en) | 1992-11-27 | 1998-05-12 | Cancer Research Campaign Technology Limited | Nitroaniline derivatives and their use as anti-tumour agents |
US5306727A (en) | 1993-04-30 | 1994-04-26 | Research Corporation Technologies, Inc. | Phosphoramidates useful as antitumor agents |
AU6859394A (en) | 1993-05-25 | 1994-12-20 | Auckland Uniservices Limited | Nitrobenzyl mustard quaternary salts and their use as hypoxia-selective cytotoxic agents |
PT648503E (pt) | 1993-09-22 | 2000-11-30 | Hoechst Ag | Pro-profarmacos, sua producao e utilizacao |
JPH07309761A (ja) | 1994-05-20 | 1995-11-28 | Kyowa Hakko Kogyo Co Ltd | デュオカルマイシン誘導体の安定化法 |
US5659061A (en) * | 1995-04-20 | 1997-08-19 | Drug Innovation & Design, Inc. | Tumor protease activated prodrugs of phosphoramide mustard analogs with toxification and detoxification functionalities |
GB9516943D0 (en) | 1995-08-18 | 1995-10-18 | Cancer Soc Auckland Div Nz Inc | Novel cyclopropylindoles and their secoprecursors,and their use as prodrugs |
US6218519B1 (en) | 1996-04-12 | 2001-04-17 | Pro-Neuron, Inc. | Compounds and methods for the selective treatment of cancer and bacterial infections |
US5728271A (en) | 1996-05-20 | 1998-03-17 | Rti Resource Transforms International Ltd. | Energy efficient liquefaction of biomaterials by thermolysis |
AU725988C (en) | 1996-05-20 | 2007-11-15 | Dynamotive Energy Systems Corporation | Energy efficient liquefaction of biomaterials by thermolysis |
US6130237A (en) | 1996-09-12 | 2000-10-10 | Cancer Research Campaign Technology Limited | Condensed N-aclyindoles as antitumor agents |
US6251933B1 (en) | 1996-12-13 | 2001-06-26 | The Cancer Research Campaign Technology Limited | Seco precursors of cyclopropylindolines and their use as prodrugs |
DE19720312A1 (de) | 1997-05-15 | 1998-11-19 | Hoechst Ag | Zubereitung mit erhöhter in vivo Verträglichkeit |
US6017948A (en) | 1998-10-30 | 2000-01-25 | Supergen, Inc. | Water-miscible pharmaceutical compositions |
US7914994B2 (en) | 1998-12-24 | 2011-03-29 | Cepheid | Method for separating an analyte from a sample |
US6240925B1 (en) | 1999-03-23 | 2001-06-05 | Cynosure, Inc. | Photothermal vascular targeting with bioreductive agents |
GB9909612D0 (en) | 1999-04-26 | 1999-06-23 | Cancer Res Campaign Tech | N-protected amines and their use as prodrugs |
JP4629238B2 (ja) * | 1999-05-24 | 2011-02-09 | サザン・リサーチ・インスティテュート | イソホスホアミドマスタード・アナログ及びその使用 |
US6649193B1 (en) | 1999-06-11 | 2003-11-18 | Henceforth Hibernia Inc. | Prophylactic therapeutic and industrial antioxidant compositions enhanced with stabilized atomic hydrogen/free electrons and methods to prepare and use such compositions |
AU5935600A (en) * | 1999-07-14 | 2001-01-30 | Richard F. Borch | Phosphoramide compounds |
JP2004538240A (ja) | 2000-03-31 | 2004-12-24 | パーデュー・リサーチ・ファウンデーション | ホスホラミデートおよびそのための方法 |
EP1243276A1 (fr) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Prodrogues activables à séparateurs allongés et multiples |
JP2005508838A (ja) | 2001-03-23 | 2005-04-07 | アフトン コーポレーション | 膵癌の組合せ治療 |
US6506739B1 (en) | 2001-05-01 | 2003-01-14 | Telik, Inc. | Bis-(N,N'-bis-(2-haloethyl)amino)phosphoramidates as antitumor agents |
IL154183A0 (en) | 2001-05-31 | 2003-07-31 | Medarex Inc | Cytotoxins, prodrugs, linkers and stabilizers useful therefor |
FR2825926A1 (fr) | 2001-06-14 | 2002-12-20 | Sod Conseils Rech Applic | Derives d'imidazoles modulant les canaux sodiques |
US7091186B2 (en) | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
US20040009667A1 (en) | 2002-02-07 | 2004-01-15 | Etsuo Iijima | Etching method |
KR20030067275A (ko) | 2002-02-07 | 2003-08-14 | 주식회사 하이폭시 | 니트로이미다졸 및 위상 이성질화 효소 저해제를유효성분으로 포함하는 항암제 |
AU2003217606C1 (en) | 2002-02-21 | 2008-07-17 | Institute Of Virology | Soluble Form of Carbonic Anhydrase IX (s-CA IX), Assays to Detect s-CA IX, CA IXs Coexpression with HER-2/neu/c-erbB-2 and CA IX-Specific Monoclonal Antibodies to Non-Immunodominant Epitopes |
JP4227771B2 (ja) | 2002-07-17 | 2009-02-18 | 三菱重工業株式会社 | バイオマスのガス化方法 |
US6833390B2 (en) | 2002-07-22 | 2004-12-21 | Bayer Polymers Llc | Process for preparing closed-cell water-blown rigid polyurethane foams having improved mechanical properties |
DE10237931A1 (de) | 2002-08-14 | 2004-02-26 | Endress + Hauser Gmbh + Co. Kg | Vorrichtung zur Überwachung eines vorbestimmten Füllstands eines Messmediums in einem Behälter |
GEP20084367B (en) | 2003-01-09 | 2008-05-13 | Pfizer | Diazepinoindole derivatives as kinase inhibitors |
GB0306907D0 (en) | 2003-03-26 | 2003-04-30 | Angiogene Pharm Ltd | Boireductively-activated prodrugs |
GB0306908D0 (en) | 2003-03-26 | 2003-04-30 | Angiogene Pharm Ltd | Bioreductively activated stilbene prodrugs |
ZA200507752B (en) | 2003-03-28 | 2007-01-31 | Threshold Pharmaceuticals Inc | Compositions and methods for treating cancer |
US6855695B2 (en) | 2003-06-13 | 2005-02-15 | Vion Pharmaceuticals, Inc. | Water-soluble SHPs as novel alkylating agents |
US7340059B2 (en) | 2003-06-17 | 2008-03-04 | Intel Corporation | Programmable scrambler and De-scrambler for digital telephony equipment |
JP2005041733A (ja) | 2003-07-28 | 2005-02-17 | National Institute Of Advanced Industrial & Technology | バイオマスによる水素製造法 |
AU2005213372B2 (en) | 2004-02-06 | 2011-03-24 | Threshold Pharmaceuticals, Inc. | Anti-cancer therapies |
US7432106B2 (en) | 2004-03-24 | 2008-10-07 | Applied Biosystems Inc. | Liquid processing device including gas trap, and system and method |
US7482129B2 (en) | 2004-05-04 | 2009-01-27 | Institute Of Virology, Slovak Academy Of Sciences | MN/CA IX/CA9 and Renal Cancer Prognosis |
IL162713A (en) | 2004-06-24 | 2011-04-28 | Desalitech Ltd | Apparatus and methods for continuous desalination in closed circuit without containers |
TW200605885A (en) | 2004-07-29 | 2006-02-16 | Threshold Pharmaceuticals Inc | Multicyclic lonidamine analogs |
TW200612918A (en) | 2004-07-29 | 2006-05-01 | Threshold Pharmaceuticals Inc | Lonidamine analogs |
EP1819338A4 (fr) | 2004-11-22 | 2009-11-04 | Threshold Pharmaceuticals Inc | Agents anticancereux de liaison à la tubuline et leurs prodrogues |
US20070117784A1 (en) | 2005-03-04 | 2007-05-24 | Novacea, Inc. | Treatment of hyperproliferative diseases with anthraquinones |
RS52505B (en) | 2005-06-29 | 2013-04-30 | Threshold Pharmaceuticals Inc. | PHOSPHORAMIDATE ALKYLATER PRODUCTS |
EP1931769A2 (fr) | 2005-10-03 | 2008-06-18 | Genetix Pharmaceuticals Inc. | Methode de depletion selective de cellules hypoxiques |
WO2008011588A2 (fr) | 2006-07-20 | 2008-01-24 | Threshold Pharmaceuticals, Inc. | Glycoconjugués d'alkylateurs de phosphoramidate pour le traitement du cancer |
WO2008033041A1 (fr) | 2006-09-11 | 2008-03-20 | Auckland Uniservices Limited | Traitement contre le cancer |
JP2008069017A (ja) | 2006-09-12 | 2008-03-27 | Matsushita Electric Ind Co Ltd | 水素製造方法 |
US7807454B2 (en) | 2006-10-18 | 2010-10-05 | The Regents Of The University Of California | Microfluidic magnetophoretic device and methods for using the same |
WO2008076826A1 (fr) | 2006-12-13 | 2008-06-26 | Threshold Pharmaceuticals, Inc. | Agents d'alkylation pyrophosphoramide |
EP2114157B1 (fr) | 2006-12-26 | 2021-05-26 | ImmunoGenesis, Inc. | Promédicament d'alkylation de phosphoramidate pour le traitement du cancer |
JP5174411B2 (ja) | 2007-09-28 | 2013-04-03 | 独立行政法人石油天然ガス・金属鉱物資源機構 | 管式リフォーマーの有効熱利用方法 |
US8216607B2 (en) | 2008-03-17 | 2012-07-10 | Roger Williams Hospital | Combination of ceramide and gemcitabine for inducing cell death and uses thereof in treating cancer |
CN104043125B (zh) | 2008-04-10 | 2018-01-12 | 弗吉尼亚州立邦联大学 | 诱导肿瘤缺氧以治疗癌症 |
EP2706059A1 (fr) | 2008-06-11 | 2014-03-12 | Genentech, Inc. | Diazacarbazoles et procédés d'utilisation |
JP4665021B2 (ja) | 2008-09-03 | 2011-04-06 | 三菱重工業株式会社 | バイオマスのガス化方法 |
WO2010048330A1 (fr) | 2008-10-21 | 2010-04-29 | Threshold Pharmaceuticals, Inc. | Traitement du cancer à l’aide de promédicaments activés par l’hypoxie |
US8281672B2 (en) | 2009-03-20 | 2012-10-09 | Pbs Biotech, Inc. | Automatable aseptic sample withdrawal system |
US20120114637A1 (en) | 2009-05-04 | 2012-05-10 | Santen Pharmaceutical Co., Ltd. | Mtor pathway inhibitors for treating ocular disorders |
US20110135739A1 (en) | 2009-11-06 | 2011-06-09 | Bennett Carter | Oral Formulations of a Hedgehog Pathway Inhibitor |
JP5659536B2 (ja) | 2010-03-31 | 2015-01-28 | 新日鐵住金株式会社 | タール含有ガスの改質用触媒及びその製造方法、並びにタール含有ガスの改質方法 |
AU2011276590A1 (en) | 2010-06-28 | 2013-01-31 | Threshold Pharmaceuticals, Inc. | Treatment of blood cancer |
RU2597844C2 (ru) | 2010-07-12 | 2016-09-20 | Тресхолд Фармасьютикалз, Инк. | Введение гипоксически активируемых пролекарств и средств, препятствующих ангиогенезу, для лечения рака |
WO2012008860A2 (fr) | 2010-07-16 | 2012-01-19 | Auckland Uniservices Limited | Enzymes nitroréductases bactériennes et procédés associés |
CN103458896B (zh) | 2011-04-01 | 2016-02-10 | 施瑞修德制药公司 | 用于治疗癌症的方法 |
EP2696858A4 (fr) | 2011-04-15 | 2014-09-03 | Threshold Pharmaceuticals Inc | Forme posologique unitaire pour administration orale |
JP5805989B2 (ja) | 2011-04-26 | 2015-11-10 | 大塚電子株式会社 | 電気泳動移動度測定用セル並びにそれを用いた測定装置及び測定方法 |
MY178682A (en) | 2011-12-20 | 2020-10-20 | Biomass Energy Corp | Method and device for producing synthetic gas and method and device for synthesizing liquid fuel |
US20150005262A1 (en) | 2011-12-22 | 2015-01-01 | Threshold Pharmaceuticals, Inc. | Hypoxia activated prodrugs and mtor inhibitors for treating cancer |
WO2013116385A1 (fr) | 2012-01-31 | 2013-08-08 | Threshold Pharmaceuticals, Inc. | Biomarqueur de prédiction pour thérapie à base de promédicament activé par hypoxie |
-
2006
- 2006-06-29 RS RS20120449A patent/RS52505B/en unknown
- 2006-06-29 PL PL06786161T patent/PL1896040T3/pl unknown
- 2006-06-29 KR KR1020087002436A patent/KR101198571B1/ko active IP Right Grant
- 2006-06-29 ES ES11157963.7T patent/ES2579235T3/es active Active
- 2006-06-29 TW TW095123590A patent/TWI384989B/zh active
- 2006-06-29 CN CN201210251557.3A patent/CN102746336B/zh active Active
- 2006-06-29 US US11/993,822 patent/US8003625B2/en active Active
- 2006-06-29 AU AU2006263433A patent/AU2006263433B8/en active Active
- 2006-06-29 EP EP11157963.7A patent/EP2336141B1/fr active Active
- 2006-06-29 BR BRPI0612845A patent/BRPI0612845A8/pt active Search and Examination
- 2006-06-29 WO PCT/US2006/025881 patent/WO2007002931A2/fr active Application Filing
- 2006-06-29 ES ES06786161T patent/ES2389532T3/es active Active
- 2006-06-29 ZA ZA200800314A patent/ZA200800314B/xx unknown
- 2006-06-29 SI SI200631455T patent/SI1896040T1/sl unknown
- 2006-06-29 PT PT06786161T patent/PT1896040E/pt unknown
- 2006-06-29 RU RU2008103195/04A patent/RU2414475C2/ru not_active IP Right Cessation
- 2006-06-29 CN CN2006800300828A patent/CN101501054B/zh active Active
- 2006-06-29 EP EP06786161A patent/EP1896040B1/fr active Active
- 2006-06-29 NZ NZ565378A patent/NZ565378A/en not_active IP Right Cessation
- 2006-06-29 DK DK06786161.7T patent/DK1896040T3/da active
- 2006-06-29 CA CA2613312A patent/CA2613312C/fr active Active
- 2006-06-29 JP JP2008519666A patent/JP5180824B2/ja active Active
-
2007
- 2007-12-19 IL IL188236A patent/IL188236A/en active IP Right Grant
-
2008
- 2008-01-23 NO NO20080442A patent/NO334420B1/no not_active IP Right Cessation
- 2008-08-26 HK HK08109465.9A patent/HK1113754A1/xx unknown
-
2011
- 2011-05-05 AU AU2011202075A patent/AU2011202075B8/en active Active
- 2011-06-17 US US13/163,303 patent/US8507464B2/en active Active
-
2012
- 2012-05-16 JP JP2012112647A patent/JP5781007B2/ja active Active
- 2012-10-05 HR HRP20120803TT patent/HRP20120803T1/hr unknown
- 2012-10-23 CY CY20121100999T patent/CY1113250T1/el unknown
-
2013
- 2013-07-12 US US13/941,261 patent/US8664204B2/en active Active
- 2013-12-10 US US14/102,213 patent/US9226932B2/en active Active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2012153722A5 (fr) | ||
JP2016501221A5 (fr) | ||
JP2017525730A5 (fr) | ||
JP2015078199A5 (fr) | ||
JP2020514311A5 (fr) | ||
JP2016538344A5 (fr) | ||
JP2015533176A5 (fr) | ||
JP2013544846A5 (fr) | ||
JP2009514881A5 (fr) | ||
JP2016526540A5 (fr) | ||
NZ628078A (en) | Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione | |
JP2016504365A5 (fr) | ||
JP2015512398A5 (fr) | ||
JP2016503414A5 (fr) | ||
JP2017530171A5 (fr) | ||
JP2013535491A5 (fr) | ||
JP2016525135A5 (fr) | ||
JP2017511321A5 (fr) | ||
JP2015508103A5 (fr) | ||
JP2022071077A5 (fr) | ||
JP2017507175A5 (fr) | ||
JP2017526662A5 (fr) | ||
JP2016512831A5 (fr) | ||
JP2019533651A5 (fr) | ||
JP2017524013A5 (fr) |